Last reviewed · How we verify
Alkotinib
At a glance
| Generic name | Alkotinib |
|---|---|
| Also known as | ZG0418 |
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (PHASE2)
- Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (PHASE1)
- To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alkotinib CI brief — competitive landscape report
- Alkotinib updates RSS · CI watch RSS
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd portfolio CI